±è¼º±Ô(68³âÁ¹) ¸í¿¹ ±³¼ö´Ô ¸ðÄ£»ó
Àå»óÈ£(81Á¹, ¿¬¼¼³»°ú) ¼±»ý´Ô ¸ðÄ£»ó
2015³â ¼¼È£È¸ Á¤±â °¡À» »êÇà ¾È³»
ÀÌÀåÈÆ(¿¬¼¼81Á¹, ÀÌÀåÈÆ³»°ú) µ¿¹® ºùºÎ»ó
Á¤ÀçÈ£(¿¬¼¼97³âÁ¹, ±¹Á¦¼º¸ðº´¿ø)µ¿¹® ¸ð..
°³²¼¼ºê¶õ½ºº´¿ø ¾Èö¹Î±³¼ö´Ô Â÷³² °áÈ¥..
¼ÕÈñ¿µ (¿¬¼¼ 75³âÁ¹)µ¿¹®ºÎÄ£»ó
±è¼¼±Ô ±³¼ö´Ô(¼¼ºê¶õ½ºº´¿ø) ºÎÄ£»ó
260616 Cystic Lung Disease
260512 Confronting Lung Cancer duri..
260414 Organizing Pneumonia
260408 Inhaled Treprostinil for Idi.. 
BLESS study 2013 JAMA
BAT study JAMA 2013
EMBRACE study 2013 lancet
macrolide resistance lancet rev..
macrolide cardiac risk AJRCCM 2..
ANCA associated ILD review2 